Therapeutic Potential of Liraglutide for Diabetes-Periodontitis Comorbidity: Killing Two Birds with One Stone

J Diabetes Res. 2022 Jul 6:2022:8260111. doi: 10.1155/2022/8260111. eCollection 2022.

Abstract

Background: The relationship between diabetes and periodontitis is bidirectional, and there is now consensus that periodontitis and diabetes are comorbid. There is a quest for a drug that can be used to treat both conditions simultaneously. This study evaluated the anti-inflammatory and osteoprotective effects of liraglutide (LIRA) on periodontitis in diabetic rats.

Methods: Male Wistar rats (n = 46) were randomly divided into four groups: control group (n = 8), LIRA group (n = 8), diabetes-associated periodontitis+0.9% saline group (diabetic periodontitis (DP)+NaCl group, n = 15), and diabetes-associated periodontitis+LIRA group (DP+LIRA group, n = 15). LIRA treatment lasted for 4 weeks (300 μg/kg/d) after establishment of a rat model of DP. The expression of IL-6, TNF-α, and IL-1β was detected by enzyme-linked immunosorbent assay. The morphological changes of periodontal tissues were observed by hematoxylin-eosin staining. The absorption of alveolar bone and its ultrastructural changes were observed by histomorphometry and microcomputed tomography. The expression of receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG) in alveolar bone was detected by immunohistochemistry. The levels of Runx2 mRNA and ALP mRNA in the gingival epithelium were examined by quantitative real-time polymerase chain reaction.

Results: LIRA decreased alveolar bone resorption, improved the microstructure of alveolar bone, and reduced periodontal inflammation and damage (P < 0.05). LIRA also reduced blood glucose level and inhibited the secretion of serum IL-6, TNF-α, and IL-1β (P < 0.05). In addition, after treatment with LIRA, the ratio of RANKL/OPG was reduced, and the expression levels of ALP mRNA and Runx2 mRNA were upregulated (P < 0.05).

Conclusions: LIRA not only controls blood glucose level but also reduces inflammation and bone loss and enhances osteogenic differentiation in diabetes-associated periodontitis. Those indicate that LIRA may be used as a potential medicine for the adjunctive therapy of diabetes-periodontitis comorbidity.

Publication types

  • Randomized Controlled Trial, Veterinary

MeSH terms

  • Alveolar Bone Loss* / drug therapy
  • Animals
  • Blood Glucose
  • Comorbidity
  • Core Binding Factor Alpha 1 Subunit
  • Diabetes Mellitus, Experimental* / complications
  • Diabetes Mellitus, Experimental* / drug therapy
  • Inflammation
  • Interleukin-6 / metabolism
  • Liraglutide / pharmacology
  • Liraglutide / therapeutic use
  • Male
  • Osteogenesis
  • Osteoprotegerin / genetics
  • Osteoprotegerin / therapeutic use
  • Periodontitis* / complications
  • Periodontitis* / drug therapy
  • Periodontitis* / genetics
  • RANK Ligand
  • RNA, Messenger
  • Rats
  • Rats, Wistar
  • Tumor Necrosis Factor-alpha / metabolism
  • X-Ray Microtomography

Substances

  • Blood Glucose
  • Core Binding Factor Alpha 1 Subunit
  • Interleukin-6
  • Osteoprotegerin
  • RANK Ligand
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Liraglutide